Central giant cell granuloma: a decade of institutional experience and curative potential of neoadjuvant denosumab
Authors' conclusion
This study demonstrates efficacy of denosumab in the treatment of CGCG both as initial and final treatment and as neo-adjuvant treatment prior to surgical resection.
Study context
- Population
- Patients with central giant cell granuloma (CGCG) of the maxilla and/or mandible
- Participants
- 12 patients
- Outcome
- Clinical and radiologic response
Methodological detailssingle-institution
- Single-institution
Main finding
As reported in the abstract
Clinical and radiologic response seen in all patients
12
Mean denosumab doses to clinical response
3
Mean denosumab doses to radiologic response
6
Observational data: associations, not effects.
Safety
- Medication related osteonecrosis of the jaw
- 0
- Adverse events included hypocalcemia and hypercalcemia
Original publication
Central giant cell granuloma: a decade of institutional experience and curative potential of neoadjuvant denosumab. J Bone Miner Res. Published 16 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →